SCHEMBL12481032

SCHEMBL12481032

Fc1ccc2c(c1)c(Cl)nc1ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.43
▸ GRM2 Q14416 1/20 0.43
▸ KMT2A Q03164 4/20 0.42
▸ ACHE P22303 1/20 0.41
▸ RXFP1 Q9HBX9 2/20 0.41
▸ GPR3 P46089 1/20 0.41
▸ ADORA2A P29274 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ HCRTR1 O43613 1/20 0.40
▸ METAP1 P53582 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ APAF1 O14727 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ MITF O75030 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.38
▸ IDO1 P14902 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12481107 0.87 ACHE (0.42) MAOAMAOBTDP1GRM2KMT2A
SCHEMBL516091 0.80 TDP1 (0.59) MAOAMAOBTDP1KMT2AACHE
SCHEMBL17752901 0.79 HTT (0.45) MAOAMAOBTDP1KMT2ARXFP1
SCHEMBL3854784 0.79 GPR3 (0.66) KMT2AGPR3ADORA2AMEN1HCRTR1
SCHEMBL12480311 0.79 KMT2A (0.41) GRM2KMT2AACHERXFP1GPR3
SCHEMBL28833010 0.78 KMT2A (0.39) MAOAMAOBGRM2KMT2AACHE
SCHEMBL840416 0.75 CLK1 (0.51) MAOATDP1KMT2AACHEADORA2A
SCHEMBL5211154 0.75 POLB (0.47) TDP1KMT2AGPR3MEN1HCRTR1
SCHEMBL13975112 0.75 PKM (0.48) TDP1GPR3KDM4EPKML3MBTL1
SCHEMBL19546465 0.73 HPRT1 (0.50) MAOBGPR3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8951964-B2 Phenanthridine macrocyclic hepatitis C serine protease inhibitors ABBVIE INC. (US) 2015-02-10 — — US disclosed
US-8951964-B2 Phenanthridine macrocyclic hepatitis C serine protease inhibitors ABBVIE INC. (US) 2015-02-10 — — US disclosed
US-8951964-B2 Phenanthridine macrocyclic hepatitis C serine protease inhibitors ABBVIE INC. (US) 2015-02-10 — — US disclosed
EP-2658858-A2 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS Enanta Pharmaceuticals, Inc. (US) 2013-11-06 — — EP disclosed
US-20120295842-A1 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBVIE INC. 2012-11-22 — — US disclosed
US-20120295842-A1 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBVIE INC. 2012-11-22 — — US disclosed
US-20120295842-A1 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBVIE INC. 2012-11-22 — — US disclosed
WO-2012092411-A2 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2012-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295842-A1 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS TMPRSS15, HPN, PRSS1 MAOA 2125/4885MAOB 1938/4885TDP1 2805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback